<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01136408</url>
  </required_header>
  <id_info>
    <org_study_id>1160.49</org_study_id>
    <nct_id>NCT01136408</nct_id>
  </id_info>
  <brief_title>A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin</brief_title>
  <official_title>Open Label, Randomised Exploratory Dose Response Study in Pharmacodynamics and Safety of BIBR 1048 (110 mg Twice Daily (b.i.d.) and 150 mg b.i.d.) for 12 Weeks in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective was to evaluate the safety of dabigatran etexilate(BIBR 1048)
      administered orally at doses of 110 and 150 mg, twice daily, for 12 weeks in patients with
      non-valvular atrial fibrillation (paroxysmal, persistent or permanent) in comparison with
      warfarin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency (Occurrence Rates) of Major Bleeding Event</measure>
    <time_frame>upto 15 weeks</time_frame>
    <description>The percentage of patients with major bleeding event.
Major bleeding was defined as any bleed fulfilling one of the following conditions:
Fatal or life-threatening
Retroperitoneal, intracranial, intraocular, or intraspinal bleeding (verified by objective testing)
Bleeding requiring surgical treatment
Clinically overt bleeding leading to a transfusion (erythrocyte component transfusion or whole blood transfusion) of 4.5 units (equal to 2 units in EU/US) or more
Clinically overt bleeding leading to a fall in haemoglobin of at least 2 g/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency (Occurrence Rates) of Clinically Relevant Bleeding Event</measure>
    <time_frame>upto 15 weeks</time_frame>
    <description>The percentage of patients with clinically relevant bleeding event.
Any bleed that did not qualify as a major bleed was defined as a minor bleed; minor bleed which fulfilled one of the criteria below was defined as a clinically relevant bleeding event:
A skin haematoma of at least 25 sqcm
Spontaneous nose bleed lasting for more than 5 minutes
Macroscopic haematuria (either spontaneous or, if associated with an intervention, lasting more than 24 hours)
Spontaneous rectal bleeding (more than spotting on toilet paper)
Gingival bleeding lasting for more than 5 minutes
Bleeding leading to hospitalisation
Bleeding leading to blood transfusion (erythrocyte component transfusion or whole blood transfusion) of less than 4.5 units (equal to 2 units in EU/US)
Any other bleeding considered clinically relevant by the investigator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency (Occurrence Rates) of Nuisance Bleeding Event</measure>
    <time_frame>Upto 15 weeks</time_frame>
    <description>The percentage of patients with nuisance bleeding event
Any bleed that did not qualify as a major bleed was defined as a minor bleed; all minor bleeding events not fulfilling one of the criteria below was defined as a nuisance bleeding event:
A skin haematoma of at least 25 sqcm
Spontaneous nose bleed lasting for more than 5 minutes
Macroscopic haematuria (either spontaneous or, if associated with an intervention, lasting more than 24 hours)
Spontaneous rectal bleeding (more than spotting on toilet paper)
Gingival bleeding lasting for more than 5 minutes
Bleeding leading to hospitalisation
Bleeding leading to blood transfusion (erythrocyte component transfusion or whole blood transfusion) of less than 4.5 units (equal to 2 units in EU/US)
Any other bleeding considered clinically relevant by the investigator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and Severity of Adverse Events</measure>
    <time_frame>Upto 15 weeks</time_frame>
    <description>Intensity of event is categorised as mild, moderate and severe.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Discontinuation of the Study Drug Due to Adverse Events</measure>
    <time_frame>Upto 15 weeks</time_frame>
    <description>Discontinuation of the study drug due to adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Laboratory Test Values</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of patients with ALT, AST, alkaline phosphatase, or bilirubin exceeded the upper limit of normal (ULN) range</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency (Occurrence Rates) of a Composite Clinical Endpoint.</measure>
    <time_frame>Upto 15 weeks</time_frame>
    <description>Percentage of patients with the composite clinical endpoint (ischemic or haemorrhagic stroke (fatal or non-fatal), transient ischemic attacks, systemic embolism, myocardial infarction (fatal or non-fatal), other major adverse cardiac events, and death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency (Occurrence Rates) of Ischemic or Haemorrhagic Stroke (Fatal or Non-fatal)</measure>
    <time_frame>Upto 15 weeks</time_frame>
    <description>The percentage of patients with ischemic or haemorrhagic stroke (fatal or non-fatal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency (Occurrence Rates) of Transient Ischemic Attack</measure>
    <time_frame>Upto 15 weeks</time_frame>
    <description>The percentage of patients with transient ischemic attack</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency (Occurrence Rates) of Systemic Embolism</measure>
    <time_frame>Upto 15 weeks</time_frame>
    <description>The percentage of patients with systemic embolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency (Occurrence Rates) of Myocardial Infarction (Fatal or Non-fatal)</measure>
    <time_frame>Upto 15 weeks</time_frame>
    <description>The percentage of patients with myocardial infarction (fatal or non-fatal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency (Occurrence Rates) of Other Major Adverse Cardiac Events</measure>
    <time_frame>Upto 15 weeks</time_frame>
    <description>The percentage of patients with other major adverse cardiac events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency (Occurrence Rates) of Death</measure>
    <time_frame>Upto 15 weeks</time_frame>
    <description>The percentage of patients with death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anticoagulation Effects Trough aPTT (Activated Partial Thromboplastin Time)</measure>
    <time_frame>Week 0,1,4 and 12</time_frame>
    <description>The blood coagulation parameter aPTT was assessed in patients allocated to the dabigatran etexilate groups at week 0, prior to drug administration and at the trough at week 1, 4 and 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anticoagulation Effects Trough ECT (Ecarin Clotting Time)</measure>
    <time_frame>Week 0,1,4 and 12</time_frame>
    <description>The blood coagulation parameter ECT was assessed in patients allocated to the dabigatran etexilate groups at week 0, prior to drug administration and at the trough at week 1, 4 and 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anticoagulation Effects Trough INR (International Normalised Ratio)</measure>
    <time_frame>Week 0,1,4 and 12</time_frame>
    <description>The blood coagulation parameter INR was assessed in patients allocated to the dabigatran etexilate groups at week 0, prior to drug administration and at the trough at week 1, 4 and 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anticoagulation Effects Trough 11-dehydrothromboxane B2</measure>
    <time_frame>Week 0 and 12</time_frame>
    <description>Analysis based on concomitant use of aspirin compared to no aspirin users. 11-dehydrothromboxane B2 is measured in urine of patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady-state Pharmacokinetics of Total Dabigatran Trough Plasma Concentration</measure>
    <time_frame>Week 1,4 and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">174</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Dabigatran etexilate 220 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dabigatran etexilate 110 mg capsule, twice a day, oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran etexilate 300 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dabigatran etexilate 150 mg capsule, twice a day, oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose-adjusted warfarin based on target INR values</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate</intervention_name>
    <description>Dabigatran etexilate 110 mg capsule, twice a day, oral administration</description>
    <arm_group_label>Dabigatran etexilate 220 mg daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate</intervention_name>
    <description>Dabigatran etexilate 150 mg capsule, twice a day, oral administration</description>
    <arm_group_label>Dabigatran etexilate 300 mg daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Dose-adjusted warfarin based on target INR values</description>
    <arm_group_label>Warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria Inclusion criteria

          1. Patients with non-valvular atrial fibrillation (paroxysmal, persistent or permanent)

          2. Patients who had additional risk factor for thromboembolism; one or more of the
             following conditions/events:

               -  Hypertension

               -  Diabetes mellitus

               -  Left-side heart failure

               -  A previous ischemic stroke or transient ischemic attack

               -  Age 75 years or older

               -  A history of coronary artery diseases

        Exclusion criteria Exclusion criteria

          1. Patients diagnosed as having a valvular heart disease by echocardiography, or patients
             who had a history of prosthetic valve replacement or valve surgery

          2. Patients who were to receive electric defibrillation or pharmacological defibrillation
             during the study period

          3. Patients who developed stroke or transient ischemic attack within 30 days before the
             date of informed consent

          4. Patients who developed myocardial infarction or were admitted to hospital due to acute
             coronary syndrome or for percutaneous transluminal coronary angioplasty within 3
             months before the date of informed consent or patients underwent coronary stenting
             within 6 months before the date of informed consent

          5. Patients with atrial myxoma or left ventricular thrombosis

          6. Patients with contraindication to anticoagulant therapies

          7. Patients scheduled for major surgery or invasive procedure

          8. Patients having major bleeding from non-gastrointestinal organs within 6 months before
             the date of informed consent

          9. Patients with uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1160.49.024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aki-gun, Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.49.025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.49.026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.49.021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Himeji, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.49.027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Iizuka,Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.49.013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyoto, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.49.011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.49.012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.49.004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Naka-gun, Ibaragi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.49.022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okayama, Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.49.023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okayama, Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.49.006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oota, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.49.016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.49.017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.49.018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.49.019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.49.020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sakai, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.49.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.49.028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.49.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sendai, Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.49.005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinjuku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.49.014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suita, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.49.015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suita, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.49.007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokorozawa, Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.49.009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toyama, Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.49.003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tsuchiura, Ibaragi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.49.029 Nagano National Hospital</name>
      <address>
        <city>Ueda, Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.49.008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yokohama, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2010</study_first_submitted>
  <study_first_submitted_qc>June 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2010</study_first_posted>
  <results_first_submitted>November 18, 2010</results_first_submitted>
  <results_first_submitted_qc>November 18, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 17, 2010</results_first_posted>
  <last_update_submitted>February 18, 2014</last_update_submitted>
  <last_update_submitted_qc>February 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eight patients were randomised but not treated with study drug, hence resulting in 174 patients as enrolled and 166 who were actually treated.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Dabigatran Etexilate 220 mg Daily</title>
          <description>Dabigatran etexilate 110 mg capsule, twice a day, oral administration</description>
        </group>
        <group group_id="P2">
          <title>Dabigatran Etexilate 300 mg Daily</title>
          <description>Dabigatran etexilate 150 mg capsule, twice a day, oral administration</description>
        </group>
        <group group_id="P3">
          <title>Warfarin</title>
          <description>Dose-adjusted warfarin based on target INR values</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dabigatran Etexilate 220 mg Daily</title>
          <description>Dabigatran etexilate 110 mg capsule, twice a day, oral administration</description>
        </group>
        <group group_id="B2">
          <title>Dabigatran Etexilate 300 mg Daily</title>
          <description>Dabigatran etexilate 150 mg capsule, twice a day, oral administration</description>
        </group>
        <group group_id="B3">
          <title>Warfarin</title>
          <description>Dose-adjusted warfarin based on target INR values</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="62"/>
            <count group_id="B4" value="166"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.9" spread="7.5"/>
                    <measurement group_id="B2" value="68.3" spread="9.1"/>
                    <measurement group_id="B3" value="67.4" spread="8.8"/>
                    <measurement group_id="B4" value="68.4" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency (Occurrence Rates) of Major Bleeding Event</title>
        <description>The percentage of patients with major bleeding event.
Major bleeding was defined as any bleed fulfilling one of the following conditions:
Fatal or life-threatening
Retroperitoneal, intracranial, intraocular, or intraspinal bleeding (verified by objective testing)
Bleeding requiring surgical treatment
Clinically overt bleeding leading to a transfusion (erythrocyte component transfusion or whole blood transfusion) of 4.5 units (equal to 2 units in EU/US) or more
Clinically overt bleeding leading to a fall in haemoglobin of at least 2 g/dL</description>
        <time_frame>upto 15 weeks</time_frame>
        <population>Safety set was used for safety endpoints. Full analysis set was used for efficacy endpoints. The safety set comprises all patients who were treated with trial medication at least once. The full analysis set comprises all patients who were randomised and treated with trial medication at least once. No data was imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 220 mg Daily</title>
            <description>Dabigatran etexilate 110 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 300 mg Daily</title>
            <description>Dabigatran etexilate 150 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O3">
            <title>Warfarin</title>
            <description>Dose-adjusted warfarin based on target INR values</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency (Occurrence Rates) of Major Bleeding Event</title>
          <description>The percentage of patients with major bleeding event.
Major bleeding was defined as any bleed fulfilling one of the following conditions:
Fatal or life-threatening
Retroperitoneal, intracranial, intraocular, or intraspinal bleeding (verified by objective testing)
Bleeding requiring surgical treatment
Clinically overt bleeding leading to a transfusion (erythrocyte component transfusion or whole blood transfusion) of 4.5 units (equal to 2 units in EU/US) or more
Clinically overt bleeding leading to a fall in haemoglobin of at least 2 g/dL</description>
          <population>Safety set was used for safety endpoints. Full analysis set was used for efficacy endpoints. The safety set comprises all patients who were treated with trial medication at least once. The full analysis set comprises all patients who were randomised and treated with trial medication at least once. No data was imputed.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.7"/>
                    <measurement group_id="O3" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency (Occurrence Rates) of Clinically Relevant Bleeding Event</title>
        <description>The percentage of patients with clinically relevant bleeding event.
Any bleed that did not qualify as a major bleed was defined as a minor bleed; minor bleed which fulfilled one of the criteria below was defined as a clinically relevant bleeding event:
A skin haematoma of at least 25 sqcm
Spontaneous nose bleed lasting for more than 5 minutes
Macroscopic haematuria (either spontaneous or, if associated with an intervention, lasting more than 24 hours)
Spontaneous rectal bleeding (more than spotting on toilet paper)
Gingival bleeding lasting for more than 5 minutes
Bleeding leading to hospitalisation
Bleeding leading to blood transfusion (erythrocyte component transfusion or whole blood transfusion) of less than 4.5 units (equal to 2 units in EU/US)
Any other bleeding considered clinically relevant by the investigator</description>
        <time_frame>upto 15 weeks</time_frame>
        <population>Safety set was used for safety endpoints. Full analysis set was used for efficacy endpoints. The safety set comprises all patients who were treated with trial medication at least once. The full analysis set comprises all patients who were randomised and treated with trial medication at least once. No data was imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 220 mg Daily</title>
            <description>Dabigatran etexilate 110 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 300 mg Daily</title>
            <description>Dabigatran etexilate 150 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O3">
            <title>Warfarin</title>
            <description>Dose-adjusted warfarin based on target INR values</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency (Occurrence Rates) of Clinically Relevant Bleeding Event</title>
          <description>The percentage of patients with clinically relevant bleeding event.
Any bleed that did not qualify as a major bleed was defined as a minor bleed; minor bleed which fulfilled one of the criteria below was defined as a clinically relevant bleeding event:
A skin haematoma of at least 25 sqcm
Spontaneous nose bleed lasting for more than 5 minutes
Macroscopic haematuria (either spontaneous or, if associated with an intervention, lasting more than 24 hours)
Spontaneous rectal bleeding (more than spotting on toilet paper)
Gingival bleeding lasting for more than 5 minutes
Bleeding leading to hospitalisation
Bleeding leading to blood transfusion (erythrocyte component transfusion or whole blood transfusion) of less than 4.5 units (equal to 2 units in EU/US)
Any other bleeding considered clinically relevant by the investigator</description>
          <population>Safety set was used for safety endpoints. Full analysis set was used for efficacy endpoints. The safety set comprises all patients who were treated with trial medication at least once. The full analysis set comprises all patients who were randomised and treated with trial medication at least once. No data was imputed.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="8.6"/>
                    <measurement group_id="O3" value="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency (Occurrence Rates) of Nuisance Bleeding Event</title>
        <description>The percentage of patients with nuisance bleeding event
Any bleed that did not qualify as a major bleed was defined as a minor bleed; all minor bleeding events not fulfilling one of the criteria below was defined as a nuisance bleeding event:
A skin haematoma of at least 25 sqcm
Spontaneous nose bleed lasting for more than 5 minutes
Macroscopic haematuria (either spontaneous or, if associated with an intervention, lasting more than 24 hours)
Spontaneous rectal bleeding (more than spotting on toilet paper)
Gingival bleeding lasting for more than 5 minutes
Bleeding leading to hospitalisation
Bleeding leading to blood transfusion (erythrocyte component transfusion or whole blood transfusion) of less than 4.5 units (equal to 2 units in EU/US)
Any other bleeding considered clinically relevant by the investigator</description>
        <time_frame>Upto 15 weeks</time_frame>
        <population>Safety set was used for safety endpoints. Full analysis set was used for efficacy endpoints. The safety set comprises all patients who were treated with trial medication at least once. The full analysis set comprises all patients who were randomised and treated with trial medication at least once. No data was imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 220 mg Daily</title>
            <description>Dabigatran etexilate 110 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 300 mg Daily</title>
            <description>Dabigatran etexilate 150 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O3">
            <title>Warfarin</title>
            <description>Dose-adjusted warfarin based on target INR values</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency (Occurrence Rates) of Nuisance Bleeding Event</title>
          <description>The percentage of patients with nuisance bleeding event
Any bleed that did not qualify as a major bleed was defined as a minor bleed; all minor bleeding events not fulfilling one of the criteria below was defined as a nuisance bleeding event:
A skin haematoma of at least 25 sqcm
Spontaneous nose bleed lasting for more than 5 minutes
Macroscopic haematuria (either spontaneous or, if associated with an intervention, lasting more than 24 hours)
Spontaneous rectal bleeding (more than spotting on toilet paper)
Gingival bleeding lasting for more than 5 minutes
Bleeding leading to hospitalisation
Bleeding leading to blood transfusion (erythrocyte component transfusion or whole blood transfusion) of less than 4.5 units (equal to 2 units in EU/US)
Any other bleeding considered clinically relevant by the investigator</description>
          <population>Safety set was used for safety endpoints. Full analysis set was used for efficacy endpoints. The safety set comprises all patients who were treated with trial medication at least once. The full analysis set comprises all patients who were randomised and treated with trial medication at least once. No data was imputed.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6"/>
                    <measurement group_id="O2" value="29.3"/>
                    <measurement group_id="O3" value="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency (Occurrence Rates) of a Composite Clinical Endpoint.</title>
        <description>Percentage of patients with the composite clinical endpoint (ischemic or haemorrhagic stroke (fatal or non-fatal), transient ischemic attacks, systemic embolism, myocardial infarction (fatal or non-fatal), other major adverse cardiac events, and death)</description>
        <time_frame>Upto 15 weeks</time_frame>
        <population>Safety set was used for safety endpoints. Full analysis set was used for efficacy endpoints. The safety set comprises all patients who were treated with trial medication at least once. The full analysis set comprises all patients who were randomised and treated with trial medication at least once. No data was imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 220 mg Daily</title>
            <description>Dabigatran etexilate 110 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 300 mg Daily</title>
            <description>Dabigatran etexilate 150 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O3">
            <title>Warfarin</title>
            <description>Dose-adjusted warfarin based on target INR values</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency (Occurrence Rates) of a Composite Clinical Endpoint.</title>
          <description>Percentage of patients with the composite clinical endpoint (ischemic or haemorrhagic stroke (fatal or non-fatal), transient ischemic attacks, systemic embolism, myocardial infarction (fatal or non-fatal), other major adverse cardiac events, and death)</description>
          <population>Safety set was used for safety endpoints. Full analysis set was used for efficacy endpoints. The safety set comprises all patients who were treated with trial medication at least once. The full analysis set comprises all patients who were randomised and treated with trial medication at least once. No data was imputed.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency (Occurrence Rates) of Ischemic or Haemorrhagic Stroke (Fatal or Non-fatal)</title>
        <description>The percentage of patients with ischemic or haemorrhagic stroke (fatal or non-fatal)</description>
        <time_frame>Upto 15 weeks</time_frame>
        <population>Safety set was used for safety endpoints. Full analysis set was used for efficacy endpoints. The safety set comprises all patients who were treated with trial medication at least once. The full analysis set comprises all patients who were randomised and treated with trial medication at least once. No data was imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 220 mg Daily</title>
            <description>Dabigatran etexilate 110 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 300 mg Daily</title>
            <description>Dabigatran etexilate 150 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O3">
            <title>Warfarin</title>
            <description>Dose-adjusted warfarin based on target INR values</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency (Occurrence Rates) of Ischemic or Haemorrhagic Stroke (Fatal or Non-fatal)</title>
          <description>The percentage of patients with ischemic or haemorrhagic stroke (fatal or non-fatal)</description>
          <population>Safety set was used for safety endpoints. Full analysis set was used for efficacy endpoints. The safety set comprises all patients who were treated with trial medication at least once. The full analysis set comprises all patients who were randomised and treated with trial medication at least once. No data was imputed.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency (Occurrence Rates) of Transient Ischemic Attack</title>
        <description>The percentage of patients with transient ischemic attack</description>
        <time_frame>Upto 15 weeks</time_frame>
        <population>Safety set was used for safety endpoints. Full analysis set was used for efficacy endpoints. The safety set comprises all patients who were treated with trial medication at least once. The full analysis set comprises all patients who were randomised and treated with trial medication at least once. No data was imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 220 mg Daily</title>
            <description>Dabigatran etexilate 110 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 300 mg Daily</title>
            <description>Dabigatran etexilate 150 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O3">
            <title>Warfarin</title>
            <description>Dose-adjusted warfarin based on target INR values</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency (Occurrence Rates) of Transient Ischemic Attack</title>
          <description>The percentage of patients with transient ischemic attack</description>
          <population>Safety set was used for safety endpoints. Full analysis set was used for efficacy endpoints. The safety set comprises all patients who were treated with trial medication at least once. The full analysis set comprises all patients who were randomised and treated with trial medication at least once. No data was imputed.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency (Occurrence Rates) of Systemic Embolism</title>
        <description>The percentage of patients with systemic embolism</description>
        <time_frame>Upto 15 weeks</time_frame>
        <population>Safety set was used for safety endpoints. Full analysis set was used for efficacy endpoints. The safety set comprises all patients who were treated with trial medication at least once. The full analysis set comprises all patients who were randomised and treated with trial medication at least once. No data was imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 220 mg Daily</title>
            <description>Dabigatran etexilate 110 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 300 mg Daily</title>
            <description>Dabigatran etexilate 150 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O3">
            <title>Warfarin</title>
            <description>Dose-adjusted warfarin based on target INR values</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency (Occurrence Rates) of Systemic Embolism</title>
          <description>The percentage of patients with systemic embolism</description>
          <population>Safety set was used for safety endpoints. Full analysis set was used for efficacy endpoints. The safety set comprises all patients who were treated with trial medication at least once. The full analysis set comprises all patients who were randomised and treated with trial medication at least once. No data was imputed.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency (Occurrence Rates) of Myocardial Infarction (Fatal or Non-fatal)</title>
        <description>The percentage of patients with myocardial infarction (fatal or non-fatal)</description>
        <time_frame>Upto 15 weeks</time_frame>
        <population>Safety set was used for safety endpoints. Full analysis set was used for efficacy endpoints. The safety set comprises all patients who were treated with trial medication at least once. The full analysis set comprises all patients who were randomised and treated with trial medication at least once. No data was imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 220 mg Daily</title>
            <description>Dabigatran etexilate 110 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 300 mg Daily</title>
            <description>Dabigatran etexilate 150 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O3">
            <title>Warfarin</title>
            <description>Dose-adjusted warfarin based on target INR values</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency (Occurrence Rates) of Myocardial Infarction (Fatal or Non-fatal)</title>
          <description>The percentage of patients with myocardial infarction (fatal or non-fatal)</description>
          <population>Safety set was used for safety endpoints. Full analysis set was used for efficacy endpoints. The safety set comprises all patients who were treated with trial medication at least once. The full analysis set comprises all patients who were randomised and treated with trial medication at least once. No data was imputed.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency (Occurrence Rates) of Other Major Adverse Cardiac Events</title>
        <description>The percentage of patients with other major adverse cardiac events</description>
        <time_frame>Upto 15 weeks</time_frame>
        <population>Safety set was used for safety endpoints. Full analysis set was used for efficacy endpoints. The safety set comprises all patients who were treated with trial medication at least once. The full analysis set comprises all patients who were randomised and treated with trial medication at least once. No data was imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 220 mg Daily</title>
            <description>Dabigatran etexilate 110 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 300 mg Daily</title>
            <description>Dabigatran etexilate 150 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O3">
            <title>Warfarin</title>
            <description>Dose-adjusted warfarin based on target INR values</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency (Occurrence Rates) of Other Major Adverse Cardiac Events</title>
          <description>The percentage of patients with other major adverse cardiac events</description>
          <population>Safety set was used for safety endpoints. Full analysis set was used for efficacy endpoints. The safety set comprises all patients who were treated with trial medication at least once. The full analysis set comprises all patients who were randomised and treated with trial medication at least once. No data was imputed.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency (Occurrence Rates) of Death</title>
        <description>The percentage of patients with death</description>
        <time_frame>Upto 15 weeks</time_frame>
        <population>Safety set was used for safety endpoints. Full analysis set was used for efficacy endpoints. The safety set comprises all patients who were treated with trial medication at least once. The full analysis set comprises all patients who were randomised and treated with trial medication at least once. No data was imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 220 mg Daily</title>
            <description>Dabigatran etexilate 110 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 300 mg Daily</title>
            <description>Dabigatran etexilate 150 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O3">
            <title>Warfarin</title>
            <description>Dose-adjusted warfarin based on target INR values</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency (Occurrence Rates) of Death</title>
          <description>The percentage of patients with death</description>
          <population>Safety set was used for safety endpoints. Full analysis set was used for efficacy endpoints. The safety set comprises all patients who were treated with trial medication at least once. The full analysis set comprises all patients who were randomised and treated with trial medication at least once. No data was imputed.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence and Severity of Adverse Events</title>
        <description>Intensity of event is categorised as mild, moderate and severe.</description>
        <time_frame>Upto 15 weeks</time_frame>
        <population>Safety set was used for safety endpoints. Full analysis set was used for efficacy endpoints. The safety set comprises all patients who were treated with trial medication at least once. The full analysis set comprises all patients who were randomised and treated with trial medication at least once. No data was imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 220 mg Daily</title>
            <description>Dabigatran etexilate 110 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 300 mg Daily</title>
            <description>Dabigatran etexilate 150 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O3">
            <title>Warfarin</title>
            <description>Dose-adjusted warfarin based on target INR values</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence and Severity of Adverse Events</title>
          <description>Intensity of event is categorised as mild, moderate and severe.</description>
          <population>Safety set was used for safety endpoints. Full analysis set was used for efficacy endpoints. The safety set comprises all patients who were treated with trial medication at least once. The full analysis set comprises all patients who were randomised and treated with trial medication at least once. No data was imputed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Discontinuation of the Study Drug Due to Adverse Events</title>
        <description>Discontinuation of the study drug due to adverse events.</description>
        <time_frame>Upto 15 weeks</time_frame>
        <population>Safety set was used for safety endpoints. Full analysis set was used for efficacy endpoints. The safety set comprises all patients who were treated with trial medication at least once. The full analysis set comprises all patients who were randomised and treated with trial medication at least once. No data was imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 220 mg Daily</title>
            <description>Dabigatran etexilate 110 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 300 mg Daily</title>
            <description>Dabigatran etexilate 150 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O3">
            <title>Warfarin</title>
            <description>Dose-adjusted warfarin based on target INR values</description>
          </group>
        </group_list>
        <measure>
          <title>Discontinuation of the Study Drug Due to Adverse Events</title>
          <description>Discontinuation of the study drug due to adverse events.</description>
          <population>Safety set was used for safety endpoints. Full analysis set was used for efficacy endpoints. The safety set comprises all patients who were treated with trial medication at least once. The full analysis set comprises all patients who were randomised and treated with trial medication at least once. No data was imputed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anticoagulation Effects Trough aPTT (Activated Partial Thromboplastin Time)</title>
        <description>The blood coagulation parameter aPTT was assessed in patients allocated to the dabigatran etexilate groups at week 0, prior to drug administration and at the trough at week 1, 4 and 12.</description>
        <time_frame>Week 0,1,4 and 12</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 220 mg Daily</title>
            <description>Dabigatran etexilate 110 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 300 mg Daily</title>
            <description>Dabigatran etexilate 150 mg capsule, twice a day, oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Anticoagulation Effects Trough aPTT (Activated Partial Thromboplastin Time)</title>
          <description>The blood coagulation parameter aPTT was assessed in patients allocated to the dabigatran etexilate groups at week 0, prior to drug administration and at the trough at week 1, 4 and 12.</description>
          <population>Full Analysis Set</population>
          <units>seconds</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 0, N=46 , N=58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" spread="12.7"/>
                    <measurement group_id="O2" value="34.0" spread="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 1, N=41, N=55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.2" spread="16.4"/>
                    <measurement group_id="O2" value="45.0" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 4, N=40, N=50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" spread="16.2"/>
                    <measurement group_id="O2" value="45.0" spread="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12, N=40, N=48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.8" spread="17.3"/>
                    <measurement group_id="O2" value="44.1" spread="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anticoagulation Effects Trough ECT (Ecarin Clotting Time)</title>
        <description>The blood coagulation parameter ECT was assessed in patients allocated to the dabigatran etexilate groups at week 0, prior to drug administration and at the trough at week 1, 4 and 12.</description>
        <time_frame>Week 0,1,4 and 12</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 220 mg Daily</title>
            <description>Dabigatran etexilate 110 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 300 mg Daily</title>
            <description>Dabigatran etexilate 150 mg capsule, twice a day, oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Anticoagulation Effects Trough ECT (Ecarin Clotting Time)</title>
          <description>The blood coagulation parameter ECT was assessed in patients allocated to the dabigatran etexilate groups at week 0, prior to drug administration and at the trough at week 1, 4 and 12.</description>
          <population>Full Analysis Set</population>
          <units>seconds</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 0, N=46 , N=58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.6" spread="9.39"/>
                    <measurement group_id="O2" value="36.3" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 1, N=41, N=55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.4" spread="23.5"/>
                    <measurement group_id="O2" value="63.2" spread="35.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 4, N=40, N=50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4" spread="23.1"/>
                    <measurement group_id="O2" value="58.9" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12, N=40, N=48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.7" spread="24.1"/>
                    <measurement group_id="O2" value="56.9" spread="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anticoagulation Effects Trough INR (International Normalised Ratio)</title>
        <description>The blood coagulation parameter INR was assessed in patients allocated to the dabigatran etexilate groups at week 0, prior to drug administration and at the trough at week 1, 4 and 12.</description>
        <time_frame>Week 0,1,4 and 12</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 220 mg Daily</title>
            <description>Dabigatran etexilate 110 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 300 mg Daily</title>
            <description>Dabigatran etexilate 150 mg capsule, twice a day, oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Anticoagulation Effects Trough INR (International Normalised Ratio)</title>
          <description>The blood coagulation parameter INR was assessed in patients allocated to the dabigatran etexilate groups at week 0, prior to drug administration and at the trough at week 1, 4 and 12.</description>
          <population>Full Analysis Set</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 0, N=46 , N=58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="35.7"/>
                    <measurement group_id="O2" value="2.03" spread="33.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 1, N=41, N=55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread="14.0"/>
                    <measurement group_id="O2" value="1.49" spread="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 4, N=40, N=50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread="16.6"/>
                    <measurement group_id="O2" value="1.46" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12, N=39, N=49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="21.2"/>
                    <measurement group_id="O2" value="1.49" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anticoagulation Effects Trough 11-dehydrothromboxane B2</title>
        <description>Analysis based on concomitant use of aspirin compared to no aspirin users. 11-dehydrothromboxane B2 is measured in urine of patients.</description>
        <time_frame>Week 0 and 12</time_frame>
        <population>Per Protocol Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 220 mg Daily</title>
            <description>Dabigatran etexilate 110 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 300 mg Daily</title>
            <description>Dabigatran etexilate 150 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O3">
            <title>Warfarin</title>
          </group>
        </group_list>
        <measure>
          <title>Anticoagulation Effects Trough 11-dehydrothromboxane B2</title>
          <description>Analysis based on concomitant use of aspirin compared to no aspirin users. 11-dehydrothromboxane B2 is measured in urine of patients.</description>
          <population>Per Protocol Analysis Set</population>
          <units>pg/mg creatinine</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 0 without aspirin, N=34, N=43, N=37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2730" spread="80.5"/>
                    <measurement group_id="O2" value="3190" spread="65.5"/>
                    <measurement group_id="O3" value="3080" spread="52.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 0 with aspirin, N=9, N=12, N=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1890" spread="49.5"/>
                    <measurement group_id="O2" value="1480" spread="49.9"/>
                    <measurement group_id="O3" value="1660" spread="54.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12 without aspirin, N=34, N=42, N=37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3350" spread="62.8"/>
                    <measurement group_id="O2" value="3430" spread="56.5"/>
                    <measurement group_id="O3" value="3520" spread="53.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12 with aspirin, N=9, N=13, N=21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2380" spread="71.2"/>
                    <measurement group_id="O2" value="1830" spread="30.4"/>
                    <measurement group_id="O3" value="1420" spread="55.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Steady-state Pharmacokinetics of Total Dabigatran Trough Plasma Concentration</title>
        <time_frame>Week 1,4 and 12</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 220 mg Daily</title>
            <description>Dabigatran etexilate 110 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 300 mg Daily</title>
            <description>Dabigatran etexilate 150 mg capsule, twice a day, oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Steady-state Pharmacokinetics of Total Dabigatran Trough Plasma Concentration</title>
          <population>Full Analysis Set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 1, N=41, N=55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.1" spread="69.0"/>
                    <measurement group_id="O2" value="78.1" spread="75.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 4, N=40, N=50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6" spread="62.5"/>
                    <measurement group_id="O2" value="78.2" spread="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12, N=39, N=49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.0" spread="62.1"/>
                    <measurement group_id="O2" value="75.1" spread="63.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Laboratory Test Values</title>
        <description>The number of patients with ALT, AST, alkaline phosphatase, or bilirubin exceeded the upper limit of normal (ULN) range</description>
        <time_frame>12 weeks</time_frame>
        <population>Safety set was used for safety endpoints. Full analysis set was used for efficacy endpoints. The safety set comprises all patients who were treated with trial medication at least once. The full analysis set comprises all patients who were randomised and treated with trial medication at least once. No data was imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 220 mg Daily</title>
            <description>Dabigatran etexilate 110 mg capsule, twice a day, oral administration
Dabigatran etexilate: Dabigatran etexilate 110 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 300 mg Daily</title>
            <description>Dabigatran etexilate 150 mg capsule, twice a day, oral administration
Dabigatran etexilate: Dabigatran etexilate 150 mg capsule, twice a day, oral administration</description>
          </group>
          <group group_id="O3">
            <title>Warfarin</title>
            <description>Dose-adjusted warfarin based on target INR values
Warfarin: Dose-adjusted warfarin based on target INR values</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Laboratory Test Values</title>
          <description>The number of patients with ALT, AST, alkaline phosphatase, or bilirubin exceeded the upper limit of normal (ULN) range</description>
          <population>Safety set was used for safety endpoints. Full analysis set was used for efficacy endpoints. The safety set comprises all patients who were treated with trial medication at least once. The full analysis set comprises all patients who were randomised and treated with trial medication at least once. No data was imputed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT &gt; 1 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST &gt; 1 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase &gt; 1 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin &gt; 1 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First administration to end of study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dabigatran Etexilate 220 mg Daily</title>
          <description>Dabigatran etexilate 110 mg capsule, twice a day, oral administration</description>
        </group>
        <group group_id="E2">
          <title>Dabigatran Etexilate 300 mg Daily</title>
          <description>Dabigatran etexilate 150 mg capsule, twice a day, oral administration</description>
        </group>
        <group group_id="E3">
          <title>Warfarin</title>
          <description>Dose-adjusted warfarin based on target INR values</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block third degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Laryngeal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatic haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

